SS-31 + Humanin Mitochondrial Research Stack

The SS-31 + Humanin stack represents a convergence of two distinct research lineages within mitochondrial peptide science. SS-31 (Elamipretide) is a synthetic, mitochondria-targeted tetrapeptide developed to enter the inner mitochondrial membrane and physically stabilise cardiolipin — the signature phospholipid of mitochondrial architecture. Humanin is a 24-amino-acid peptide encoded within the 16S ribosomal RNA gene of mitochondrial DNA itself, later shown to also signal through cell-surface receptors as a circulating hormone. Together, they represent the two major axes by which researchers are investigating mitochondrial resilience: the structural axis (cardiolipin integrity and electron transport chain geometry) and the signalling axis (FPRL1/FPR3-mediated apoptosis suppression and STAT3-driven mitochondrial unfolded protein response). Neither compound is approved for human use in the UK; this article summarises the preclinical and early-phase clinical data on the combination as a research framework only.

Why pair SS-31 with Humanin?

The case for combining these two peptides rests on mechanistic complementarity rather than direct co-administration data. SS-31, developed by Hazel Szeto at Cornell University (Weill Cornell Medical College) and later advanced through Stealth BioTherapeutics, physically intercalates into the inner mitochondrial membrane via its alternating aromatic-cationic structure and binds cardiolipin with high selectivity. Cardiolipin is the architectural phospholipid that organises the respiratory supercomplexes — Complexes I, III and IV — into the functionally efficient "respirasomes" that maximise ATP yield from substrate oxidation. When cardiolipin is oxidised or reduced, as occurs during ischaemia, ageing and primary mitochondrial disease, the respiratory architecture fragments, electron transport slows and reactive oxygen species (ROS) production rises.

Humanin, discovered in 2001 by Yoshiko Hashimoto at Keio University in Tokyo, acts at a different level. It suppresses the mitochondrial apoptotic pathway — principally Bax-mediated cytochrome c release — via binding to the formyl peptide receptor-like 1 (FPRL1, now designated FPR3) on the cell surface and through intracellular STAT3 activation. Pinchas Cohen at the University of Southern California subsequently demonstrated that Humanin is one of a broader class of mitochondrial-derived peptides (MDPs) whose circulating plasma levels decline with age and that this decline correlates with senescence and metabolic dysregulation.

By pairing SS-31 (structural stabilisation of the inner membrane) with Humanin (signalling-level suppression of mitochondrial apoptosis and activation of the MUPR), the combination theoretically addresses both the physical failure of electron transport and the downstream cellular consequences of mitochondrial dysfunction.

Mechanism of action — each peptide

Summarised studies on the combination

No published study has administered SS-31 and Humanin in direct combination; however, the converging literature from their respective research programmes provides a strong mechanistic rationale for combined investigation.

MMPOWER-3 Phase III (Elamipretide, primary mitochondrial myopathy) — The Phase III MMPOWER-3 trial (NCT03323749), led by Amel Karaa and colleagues, enrolled adults with genetically confirmed primary mitochondrial myopathy. Participants received subcutaneous Elamipretide (40 mg/day) or placebo over 24 weeks. The primary endpoints — distance walked on the six-minute walk test and patient-reported fatigue — showed a consistent directional trend favouring Elamipretide, though the trial did not achieve statistical significance on its composite primary endpoint. Secondary endpoints including patient-reported endurance and functional capacity showed statistically significant improvement (PMID: 29540588). The trial established the 40 mg/day subcutaneous dose as the principal research reference point for SS-31 in clinical protocols.

HEART-1 trial (Elamipretide, heart failure) — Daubert and colleagues published results from the HEART-1 randomised, placebo-controlled trial in patients with heart failure. Elamipretide improved left ventricular end-systolic volume index at 4 weeks versus placebo, with a good safety profile and no significant adverse haemodynamic effects. This cardioprotective finding was mechanistically consistent with the cardiolipin-stabilisation model established in preclinical ischaemia-reperfusion work (PMID: 28711444).

Humanin — animal longevity models — Multiple rodent studies from the Cohen group at USC have demonstrated that Humanin administration extends mean lifespan in C57BL/6 mice, improves insulin sensitivity and reduces visceral adiposity. Intraperitoneal humanin analogues (HNG, with a serine-to-glycine substitution at position 14) have shown 1,000-fold greater potency than native Humanin in anti-apoptotic assays (PMID: 11371638). Lue and colleagues demonstrated that the Humanin analogue HNGF6A reduced amyloid burden and improved cognitive outcomes in the 3xTg-AD mouse model (PMID: 25878568).

Humanin plasma levels in human ageing — Yen, Kim, Wan, Mehta and Cohen demonstrated in a cross-sectional human study that circulating Humanin concentrations decline sharply with age and that higher plasma Humanin correlates with better cognitive test scores in adults over 65 (PMID: 30242226). Separately, Kim and colleagues reviewed the broader MDP class, establishing that Humanin and MOTS-c operate through complementary but non-redundant signalling axes, reinforcing the rationale for multi-peptide MDP research protocols (PMID: 28547758).

Full research protocol

The doses below reflect the research literature for each peptide individually. In the absence of combination pharmacokinetic data, the protocol uses conservative introductory doses for SS-31 to mirror the Phase II escalation design used by Karaa and colleagues.

Weekly research timeline

• Week 1 (introductory): SS-31 is started at 5 mg/day SC to allow tolerance assessment. Humanin is introduced at 10 mg every other day from day 1, as the shorter cycle means there is no time for a prolonged escalation phase.
• Weeks 2–3 (full research dose): SS-31 is escalated to 10 mg/day, mirroring the Phase II escalation design. Humanin continues at 10 mg every other day. This window corresponds to the period of peak mechanistic interest — mitochondrial structural improvement under SS-31 combined with ongoing Humanin-mediated MUPR and apoptosis suppression.
• Week 4 (taper): SS-31 is returned to the 5 mg introductory dose. Humanin continues at 10 mg every other day. The taper avoids abrupt discontinuation of the cardiolipin-stabilising signal.
• Post-cycle observation (weeks 5–8): No published washout duration exists for this specific combination. A four-week observation window before any repeat cycle is recommended, consistent with the MMPOWER clinical trial design.

Reconstitution & storage notes

SS-31 reconstitutes readily in sterile bacteriostatic water at 1–2 mg/mL. The solution is light-sensitive and should be stored in amber vials at 2–8 °C for short-term use; lyophilised powder is stable at −20 °C for up to 12 months. Humanin is a smaller, more soluble 24-amino-acid peptide that reconstitutes at 1 mg/mL in bacteriostatic water without difficulty. Both peptides should be aliquoted before freezing to avoid repeated freeze-thaw cycles, which degrade peptide integrity over time. Prepare fresh working solutions from frozen aliquots weekly.

Related research

If you are researching this mitochondrial peptide combination, you may also be interested in the Epitalon + Humanin + MOTS-c longevity stack, which extends the mitochondrial-derived peptide framework to include telomere-targeting and glucose-metabolism axes, or the MOTS-c + AOD-9604 fat loss stack, which pairs the metabolic MDP MOTS-c with a lipolytic growth-hormone fragment.

For the full underlying mechanism of action of each compound, see the per-peptide monographs at PeptideAuthority.co.uk/peptides/ss-31 and PeptideAuthority.co.uk/peptides/humanin.